Patents by Inventor Kerry L. Spear

Kerry L. Spear has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230116114
    Abstract: The present disclosure provides compounds and pharmaceutical compositions thereof. Methods of making and using the compounds are also provided. The compounds can be used for the treatment, prevention, diagnosis and/or management of various CNS disorders.
    Type: Application
    Filed: December 29, 2020
    Publication date: April 13, 2023
    Inventors: Kerry L. Spear, Douglas Burdi
  • Publication number: 20230109801
    Abstract: The present disclosure provides compounds and pharmaceutical compositions thereof. Methods of making and using the compounds are also provided. The compounds can be used for the treatment, prevention, diagnosis and/or management of various CNS disorders.
    Type: Application
    Filed: December 29, 2020
    Publication date: April 13, 2023
    Inventors: Kerry L. Spear, Douglas Burdi
  • Publication number: 20220185799
    Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
    Type: Application
    Filed: October 29, 2021
    Publication date: June 16, 2022
    Applicants: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Linghong XIE, Philip Glyn JONES, Kerry L. SPEAR, Noel Aaron POWELL, Taleen G. HANANIA, Vadim ALEXANDROV
  • Patent number: 11192885
    Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: December 7, 2021
    Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Linghong Xie, Philip Glyn Jones, Kerry L. Spear, Noel Aaron Powell, Taleen G. Hanania, Vadim Alexandrov
  • Patent number: 10640510
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: May 5, 2020
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Publication number: 20200079778
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Application
    Filed: December 6, 2018
    Publication date: March 12, 2020
    Inventors: Michele L.R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Publication number: 20190389845
    Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
    Type: Application
    Filed: May 6, 2019
    Publication date: December 26, 2019
    Applicants: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Linghong Xie, Philip Glyn JONES, Kerry L. SPEAR, Noel Aaron POWELL, Taleen G. HANANIA, Vadim ALEXANDROV
  • Patent number: 10336732
    Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: July 2, 2019
    Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Linghong Xie, Philip Glyn Jones, Kerry L. Spear, Noel Aaron Powell, Taleen G. Hanania, Vadim Alexandrov
  • Publication number: 20190135815
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Application
    Filed: December 6, 2018
    Publication date: May 9, 2019
    Inventors: Michele L.R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Publication number: 20190055204
    Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 21, 2019
    Inventors: Larry Wendell Hardy, Michele L.R. Heffernan, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Patent number: 10196399
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: February 5, 2019
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Publication number: 20190031685
    Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and neurological disorders, including, but not limited to, e.g., psychosis, schizophrenia, depression, movement disorders, and Parkinson's disease.
    Type: Application
    Filed: April 6, 2018
    Publication date: January 31, 2019
    Inventors: Philip G. Jones, Robert Lew, Kerry L. Spear, Linghong Xie
  • Patent number: 10077243
    Abstract: Provided herein are compounds of formula (I): and pharmaceutical compositions thereof, useful for the treatment of disorders mediated by metabotropic glutamate receptor 5.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: September 18, 2018
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Larry Wendell Hardy, Michele L. R. Heffernan, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Patent number: 9951088
    Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and neurological disorders, including, but not limited to, e.g., psychosis, schizophrenia, depression, movement disorders, and Parkinson's disease.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: April 24, 2018
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Philip G. Jones, Robert Lew, Kerry L. Spear, Linghong Xie
  • Publication number: 20180093974
    Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
    Type: Application
    Filed: November 21, 2017
    Publication date: April 5, 2018
    Applicants: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Linghong Xie, Philip Glyn Jones, Kerry L. Spear, Noel Aaron Powell, Taleen G. Hanania, Vadim Alexandrov
  • Publication number: 20180037585
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Application
    Filed: June 16, 2017
    Publication date: February 8, 2018
    Inventors: Michele L.R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Patent number: 9884844
    Abstract: Provided herein are heterocyclyl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: February 6, 2018
    Assignee: SUNOVION PHARMACEUTICALS, INC.
    Inventors: Qun Kevin Fang, Una Campbell, Kerry L. Spear
  • Patent number: 9856238
    Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: January 2, 2018
    Assignees: SUNOVION PHARMACEUTICALS INC., PGI DRUG DISCOVERY LLC
    Inventors: Linghong Xie, Philip Glyn Jones, Kerry L. Spear, Noel Aaron Powell, Taleen G. Hanania, Vadim Alexandrov
  • Publication number: 20170204050
    Abstract: Phenyl-substituted cyclohexylamine derivatives and methods for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.
    Type: Application
    Filed: January 30, 2017
    Publication date: July 20, 2017
    Inventors: Liming SHAO, Fengjiang WANG, Scott Christopher MALCOLM, Michael Charles HEWITT, Jianguo MA, Seth RIBE, Mark A. VARNEY, Una CAMPBELL, Sharon Rae ENGEL, Larry Wendell HARDY, Patrick KOCH, Rudy SCHREIBER, Kerry L. Spear
  • Patent number: 9708331
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: July 18, 2017
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear